Company news
AstraZeneca PLC news in 2021
AstraZeneca PLC's news releases, calls and decks from 2021, newest first.
Tagrisso approved in EU in early lung cancer
May 28, 2021
Second Price Monitoring Extn
May 27, 2021
Price Monitoring Extension
May 27, 2021
AstraZeneca prices a EUR800m bond offering
May 27, 2021
AstraZeneca prices a $7bn bond offering
May 26, 2021
EMTN programme update - publication of Prospectus
May 25, 2021
Vaxzevria COVID-19 vaccine approved in Japan
May 21, 2021
Shareholders vote in favour of Alexion acquisition
May 11, 2021
Imfinzi + tremelimumab showed survival in POSEIDON
May 7, 2021
Farxiga approved in the US for CKD
May 4, 2021
AZN: First quarter 2021 results
April 30, 2021
Selumetinib recommended for EU approval in NF1
April 26, 2021
Tagrisso adjuvant receives positive CHMP opinion
April 26, 2021
Nirsevimab Phase III trial met primary endpoint
April 26, 2021
US clearance of proposed acquisition of Alexion
April 16, 2021
Tagrisso approved in China in early lung cancer
April 14, 2021
Circular and notice of general meeting
April 12, 2021
Update on Farxiga COVID-19 DARE-19 Phase III trial
April 12, 2021
AZD1222 US Ph3 primary analysis confirms efficacy
March 25, 2021
AstraZeneca US vaccine trial met primary endpoint
March 22, 2021
Divestment of Viela shareholding completed
March 16, 2021
US supply agreement for additional AZD7442 doses
March 16, 2021
Designation of EU home member state
March 4, 2021
US court decision favours Symbicort patents
March 3, 2021
Further update on roxadustat US regulatory review
March 2, 2021
Voluntary withdrawal Imfinzi US bladder indication
February 22, 2021
Lynparza: IDMC recommend early analysis of OlympiA
February 17, 2021
AstraZeneca Non-Executive Board changes
February 11, 2021
AZN: full-year 2020 results
February 11, 2021
Divestment of Crestor in Europe completed
February 10, 2021
Update on KESTREL Phase III trial for Imfinzi
February 5, 2021
Forxiga approved in China for heart failure
February 4, 2021
AstraZeneca agrees to divest Viela shareholding
February 1, 2021
COVID-19 vaccine authorised for use by the EU
February 1, 2021
COVID-19 vaccine receives positive opinion in EU
January 29, 2021
Block listing application
January 26, 2021
Symbicort approved in China for mild asthma
January 26, 2021
Calquence approved in Japan for CLL
January 25, 2021
Calquence met primary endpoint against ibrutinib
January 25, 2021
Enhertu approved in the EU for breast cancer
January 20, 2021
Enhertu approved in the US for gastric cancer
January 18, 2021
Imfinzi new dosing approved in EU
January 15, 2021
Farxiga granted US Priority Review for CKD
January 6, 2021
Atacand divestment in over 70 countries completed
January 4, 2021
Decks in 2021
- H1 2021 Earnings Presentation
Earnings · 40 slides · Dec 8, 2021
- Q3 2021 Earnings Presentation
Earnings · 39 slides · Nov 12, 2021
- Coupa Supplier Webinar Wave 3 Japan, November 2021
Conference · 25 slides · November 2021
- European Society for Medical Oncology (ESMO) Congress 2021
Conference · 34 slides · Sep 20, 2021
- Investor Presentation (September 2021)
Investor deck · 22 slides · September 2021
- H1 2021 Earnings Presentation
Earnings · 42 slides · Jul 29, 2021
- Investor Day (June 2021)
Investor day · 40 slides · Jun 7, 2021
- Q1 2021 Earnings Presentation
Earnings · 40 slides · Apr 30, 2021
- Investor Day (March 2021)
Investor day · 13 slides · Mar 25, 2021
- Investor Day (March 2021)
Investor day · 33 slides · Mar 25, 2021
- Investor Day (March 2021)
Investor day · 13 slides · Mar 25, 2021
- Investor Day (March 2021)
Investor day · 14 slides · Mar 25, 2021
- Investor Day (March 2021)
Investor day · 13 slides · Mar 25, 2021
- FY2020 Earnings Presentation
Earnings · 39 slides · Feb 11, 2021
- Q3 2021 Earnings Presentation
Earnings · 129 slides · 2021
- Q1 2021 Earnings Presentation
Earnings · 110 slides · 2021
- Q2 2021 Earnings Presentation
Earnings · 113 slides · 2021
- FY2020 Earnings Presentation
Earnings · 114 slides · 2021